Current anti-CD47 antibodies such as magrolimab will have anemia as a side effect due to the blockade of CD47, utilized by older erythrocytes for elimination. Amitkumar Mehta, MD, UAB School of Medicine, Birmingham, AL, presents findings from a Phase Ib trial (NCT03934814) of lemzoparlimab, a novel anti-CD47 antibody, in patients with relapsed/refractory non-Hodgkin’s lymphoma. Patients were administered lemzoparlimab with rituximab in a 3+3 dose escalation trial, and lemzoparlimab demonstrated promising efficacy and safety across patients with diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL). This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
